1. Home
  2. VIR
  3. VIR News

Latest Vir Biotechnology Inc. (VIR) News on June 3, 2025

Spero Therapeutics And 2 Other Promising Penny Stocks To Watch
VIR

Simply Wall St.

5 days ago

Spero Therapeutics And 2 Other Promising Penny Stocks To Watch

Vir Biotechnology to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference 2025
VIR

Business Wire

5 days ago

Vir Biotechnology to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference 2025

Vir Biotechnology to Participate in TD Cowen 6th Annual Oncology Innovation Summit
VIR

Business Wire

13 days ago

Vir Biotechnology to Participate in TD Cowen 6th Annual Oncology Innovation Summit

VIR

Argus Research

20 days ago

VIR: Rating decreased to a SELL

Vir Biotechnology to Participate in Bank of America Securities 2025 Healthcare Conference
VIR

Business Wire

21 days ago

Vir Biotechnology to Participate in Bank of America Securities 2025 Healthcare Conference

Vir Biotechnology First Quarter 2025 Earnings: Revenues Disappoint
VIR

Simply Wall St.

24 days ago

Vir Biotechnology First Quarter 2025 Earnings: Revenues Disappoint

Vir Biotechnology Announces Preliminary 24-Week Post-End of Treatment Data for Tobevibart and Elebsiran Combinations in Chronic Hepatitis B From the MARCH Study
VIR

Business Wire

25 days ago

Vir Biotechnology Announces Preliminary 24-Week Post-End of Treatment Data for Tobevibart and Elebsiran Combinations in Chronic Hepatitis B From the MARCH Study

VIR

Thomson Reuters StreetEvents

a month ago

Q1 2025 Vir Biotechnology Inc Earnings Call

Vir Biotechnology Inc (VIR) Q1 2025 Earnings Call Highlights: Navigating Challenges with ...
VIR

GuruFocus.com

a month ago

Vir Biotechnology Inc (VIR) Q1 2025 Earnings Call Highlights: Navigating Challenges with ...

Vir Biotechnology, Inc. (VIR) Reports Q1 Loss, Lags Revenue Estimates
VIR

Zacks

a month ago

Vir Biotechnology, Inc. (VIR) Reports Q1 Loss, Lags Revenue Estimates

Vir Biotechnology Provides Corporate Update and Reports First Quarter 2025 Financial Results
VIR

Business Wire

a month ago

Vir Biotechnology Provides Corporate Update and Reports First Quarter 2025 Financial Results

VIR

Argus Research

a month ago

VIR: What does Argus have to say about VIR?

Vir Biotechnology to Provide Corporate Update and Report First Quarter 2025 Financial Results on May 7, 2025
VIR

Business Wire

a month ago

Vir Biotechnology to Provide Corporate Update and Report First Quarter 2025 Financial Results on May 7, 2025

Vir Biotechnology to Present Latest Clinical Data in Hepatitis Delta and B Programs at the European Association for the Study of the Liver (EASL) Congress 2025
VIR

Business Wire

a month ago

Vir Biotechnology to Present Latest Clinical Data in Hepatitis Delta and B Programs at the European Association for the Study of the Liver (EASL) Congress 2025

VIR

Argus Research

a month ago

VIR: What does Argus have to say about VIR?

VIR

Argus Research

2 months ago

VIR: Rating decreased to a HOLD

Vir Biotechnology, Inc. (VIR): Among Stocks Under $10 that Will Triple
VIR

Insider Monkey

2 months ago

Vir Biotechnology, Inc. (VIR): Among Stocks Under $10 that Will Triple

VIR

Argus Research

2 months ago

VIR: Rating increased to a BUY

VIR

Argus Research

2 months ago

VIR: Lowering target price to $6.00

Vir Biotechnology, Inc. (NASDAQ:VIR) is favoured by institutional owners who hold 53% of the company
VIR

Simply Wall St.

2 months ago

Vir Biotechnology, Inc. (NASDAQ:VIR) is favoured by institutional owners who hold 53% of the company

Vir Biotechnology Enrolls First Patient in Phase 3 ECLIPSE Registrational Program for Chronic Hepatitis Delta
VIR

Business Wire

3 months ago

Vir Biotechnology Enrolls First Patient in Phase 3 ECLIPSE Registrational Program for Chronic Hepatitis Delta

VIR

Argus Research

3 months ago

VIR: Lowering target price to $9.00

Analysts Have Lowered Expectations For Vir Biotechnology, Inc. (NASDAQ:VIR) After Its Latest Results
VIR

Simply Wall St.

3 months ago

Analysts Have Lowered Expectations For Vir Biotechnology, Inc. (NASDAQ:VIR) After Its Latest Results

VIR

Thomson Reuters StreetEvents

3 months ago

Q4 2024 Vir Biotechnology Inc Earnings Call

Vir Biotechnology Inc (VIR) Q4 2024 Earnings Call Highlights: Strategic Advances Amid Financial ...
VIR

GuruFocus.com

3 months ago

Vir Biotechnology Inc (VIR) Q4 2024 Earnings Call Highlights: Strategic Advances Amid Financial ...

Vir Biotechnology, Inc. (VIR) Reports Q4 Loss, Lags Revenue Estimates
VIR

Zacks

3 months ago

Vir Biotechnology, Inc. (VIR) Reports Q4 Loss, Lags Revenue Estimates

Vir Biotechnology Provides Corporate Update and Reports Fourth Quarter and Full Year 2024 Financial Results
VIR

Business Wire

3 months ago

Vir Biotechnology Provides Corporate Update and Reports Fourth Quarter and Full Year 2024 Financial Results

VIR

Argus Research

3 months ago

VIR: Rating increased to a HOLD

Vir Biotechnology to Participate in TD Cowen 45th Annual Health Care Conference
VIR

Business Wire

3 months ago

Vir Biotechnology to Participate in TD Cowen 45th Annual Health Care Conference

VIR

Argus Research

3 months ago

VIR: Raising target price to $8.00

Vir Biotechnology to Provide Corporate Update and Report Fourth Quarter and Full Year 2024 Financial Results on February 26, 2025
VIR

Business Wire

4 months ago

Vir Biotechnology to Provide Corporate Update and Report Fourth Quarter and Full Year 2024 Financial Results on February 26, 2025

VIR

Argus Research

4 months ago

VIR: What does Argus have to say about VIR?

VIR

Argus Research

4 months ago

VIR: What does Argus have to say about VIR?

Why Vir Biotechnology, Inc. (VIR) Is Skyrocketing Now
VIR

Insider Monkey

4 months ago

Why Vir Biotechnology, Inc. (VIR) Is Skyrocketing Now

VIR

Argus Research

4 months ago

VIR: What does Argus have to say about VIR?

VIR

Argus Research

5 months ago

VIR: Raising target price to $8.00

Morgan Stanley Doubles Vir Biotechnology Price Forecast - Here's Why
VIR

Benzinga

5 months ago

Morgan Stanley Doubles Vir Biotechnology Price Forecast - Here's Why

VIR Stock Up on Early Safety & Efficacy Data on Two Cancer Candidates
VIR

Zacks

5 months ago

VIR Stock Up on Early Safety & Efficacy Data on Two Cancer Candidates

VIR

Investing.com

5 months ago

Morgan Stanley upgrades Vir Biotechnology to 'overweight,' raises PT to $20

Vir Biotechnology Reports Promising Trial Results for Cancer Therapies
VIR

TipRanks

5 months ago

Vir Biotechnology Reports Promising Trial Results for Cancer Therapies

Vir Biotechnology Catapults 62% On Promising Results In Cancer Treatment
VIR

Investor's Business Daily

5 months ago

Vir Biotechnology Catapults 62% On Promising Results In Cancer Treatment

Vir Biotechnology Announces Encouraging Safety and Efficacy Data in Ongoing Dose Escalation Trials for Dual Masked T-Cell Engagers VIR-5818 in Solid Tumors and VIR-5500 in mCRPC
VIR

Business Wire

5 months ago

Vir Biotechnology Announces Encouraging Safety and Efficacy Data in Ongoing Dose Escalation Trials for Dual Masked T-Cell Engagers VIR-5818 in Solid Tumors and VIR-5500 in mCRPC

Vir Biotechnology price target lowered to $14 from $15 at BofA
VIR

TipRanks

5 months ago

Vir Biotechnology price target lowered to $14 from $15 at BofA

VIR

Argus Research

5 months ago

VIR: What does Argus have to say about VIR?

Vir Biotechnology to Present at the 43rd Annual J.P. Morgan Healthcare Conference
VIR

Business Wire

6 months ago

Vir Biotechnology to Present at the 43rd Annual J.P. Morgan Healthcare Conference

VIR

Argus Research

6 months ago

VIR: What does Argus have to say about VIR?

Vir Biotechnology Receives FDA Breakthrough Therapy Designation and EMA PRIME Designation for Tobevibart and Elebsiran in Chronic Hepatitis Delta
VIR

Business Wire

6 months ago

Vir Biotechnology Receives FDA Breakthrough Therapy Designation and EMA PRIME Designation for Tobevibart and Elebsiran in Chronic Hepatitis Delta

VIR

Argus Research

6 months ago

VIR: Lowering target price to $6.00

VIR

Argus Research

6 months ago

VIR: Raising target price to $7.00

Janux Catapults 49% On 'Unprecedented' Results In Prostate Cancer; Vir Goes For A Ride
VIR

Investor's Business Daily

6 months ago

Janux Catapults 49% On 'Unprecedented' Results In Prostate Cancer; Vir Goes For A Ride

Janux, Vir Catapult On 'Unprecedented' Results In Prostate Cancer Patients
VIR

Investor's Business Daily

6 months ago

Janux, Vir Catapult On 'Unprecedented' Results In Prostate Cancer Patients

Will Vir Biotechnology (NASDAQ:VIR) Spend Its Cash Wisely?
VIR

Simply Wall St.

6 months ago

Will Vir Biotechnology (NASDAQ:VIR) Spend Its Cash Wisely?

VIR

Argus Research

6 months ago

VIR: What does Argus have to say about VIR?

Vir Biotechnology to Host Virtual Investor Event on PRO-XTEN™ Masked T-Cell Engager Programs
VIR

Business Wire

6 months ago

Vir Biotechnology to Host Virtual Investor Event on PRO-XTEN™ Masked T-Cell Engager Programs

Vir Biotechnology to Participate in the 7th Annual Evercore ISI HealthCONx Conference
VIR

Business Wire

6 months ago

Vir Biotechnology to Participate in the 7th Annual Evercore ISI HealthCONx Conference

Vir Biotechnology Presents Positive Chronic Hepatitis Delta Clinical Trial Data and Announces Initiation of Phase 3 Registrational Program
VIR

Business Wire

6 months ago

Vir Biotechnology Presents Positive Chronic Hepatitis Delta Clinical Trial Data and Announces Initiation of Phase 3 Registrational Program

Vir Biotechnology Receives Positive Opinion on Orphan Drug Designation for Tobevibart and Elebsiran in Chronic Hepatitis Delta from European Medicines Agency
VIR

Business Wire

6 months ago

Vir Biotechnology Receives Positive Opinion on Orphan Drug Designation for Tobevibart and Elebsiran in Chronic Hepatitis Delta from European Medicines Agency

What's Going On With Liver Disease Focused Vir Biotechnology Stock Is Friday?
VIR

Benzinga

7 months ago

What's Going On With Liver Disease Focused Vir Biotechnology Stock Is Friday?

Vir Biotechnology Announces Positive End-of-Treatment Results for Tobevibart and Elebsiran Combinations in Chronic Hepatitis B from the MARCH Study at AASLD The Liver Meeting
VIR

Business Wire

7 months ago

Vir Biotechnology Announces Positive End-of-Treatment Results for Tobevibart and Elebsiran Combinations in Chronic Hepatitis B from the MARCH Study at AASLD The Liver Meeting

VIR

Argus Research

7 months ago

VIR: Lowering target price to $7.00

VIR

Argus Research

7 months ago

VIR: Rating decreased to a SELL

Analysts Have Lowered Expectations For Vir Biotechnology, Inc. (NASDAQ:VIR) After Its Latest Results
VIR

Simply Wall St.

7 months ago

Analysts Have Lowered Expectations For Vir Biotechnology, Inc. (NASDAQ:VIR) After Its Latest Results

Vir Biotechnology Third Quarter 2024 Earnings: Misses Expectations
VIR

Simply Wall St.

7 months ago

Vir Biotechnology Third Quarter 2024 Earnings: Misses Expectations

Vir Biotechnology Inc (VIR) Q3 2024 Earnings Call Highlights: Strategic Restructuring and ...
VIR

GuruFocus.com

7 months ago

Vir Biotechnology Inc (VIR) Q3 2024 Earnings Call Highlights: Strategic Restructuring and ...

Vir Biotechnology (NASDAQ:VIR) shareholders have endured a 76% loss from investing in the stock three years ago
VIR

Simply Wall St.

7 months ago

Vir Biotechnology (NASDAQ:VIR) shareholders have endured a 76% loss from investing in the stock three years ago

U.S. Drugmakers Are Breaking Up With Their Chinese Supply-Chain Partners
VIR

The Wall Street Journal

7 months ago

U.S. Drugmakers Are Breaking Up With Their Chinese Supply-Chain Partners

Vir Biotechnology, Inc. (VIR) Reports Q3 Loss, Lags Revenue Estimates
VIR

Zacks

7 months ago

Vir Biotechnology, Inc. (VIR) Reports Q3 Loss, Lags Revenue Estimates

Vir Biotechnology Reports Third Quarter 2024 Financial Results and Provides Corporate Update
VIR

Business Wire

7 months ago

Vir Biotechnology Reports Third Quarter 2024 Financial Results and Provides Corporate Update

State Street Corp's Strategic Acquisition in Vir Biotechnology Inc
VIR

GuruFocus.com

8 months ago

State Street Corp's Strategic Acquisition in Vir Biotechnology Inc

Vir Biotechnology to Provide Business Update and Report Third Quarter 2024 Financial Results on October 31, 2024
VIR

Business Wire

8 months ago

Vir Biotechnology to Provide Business Update and Report Third Quarter 2024 Financial Results on October 31, 2024

Vir Biotechnology Announces Clinical Advances Across Hepatitis Delta and Hepatitis B Programs at AASLD’s The Liver Meeting® 2024
VIR

Business Wire

8 months ago

Vir Biotechnology Announces Clinical Advances Across Hepatitis Delta and Hepatitis B Programs at AASLD’s The Liver Meeting® 2024

VIR

Argus Research

8 months ago

VIR: What does Argus have to say about VIR?

Vir Biotechnology, Inc. (NASDAQ:VIR) is largely controlled by institutional shareholders who own 53% of the company
VIR

Simply Wall St.

8 months ago

Vir Biotechnology, Inc. (NASDAQ:VIR) is largely controlled by institutional shareholders who own 53% of the company

Vir Biotechnology to Participate in the H.C. Wainwright 5th Annual Viral Hepatitis Virtual Conference
VIR

Business Wire

8 months ago

Vir Biotechnology to Participate in the H.C. Wainwright 5th Annual Viral Hepatitis Virtual Conference

Vir Biotechnology Appoints Jason O’Byrne as Chief Financial Officer
VIR

Business Wire

9 months ago

Vir Biotechnology Appoints Jason O’Byrne as Chief Financial Officer

Vir Biotechnology Announces Closing of Exclusive Worldwide License Agreement With Sanofi for Multiple Potential Best-in-Class Clinical-Stage T-Cell Engagers
VIR

Business Wire

9 months ago

Vir Biotechnology Announces Closing of Exclusive Worldwide License Agreement With Sanofi for Multiple Potential Best-in-Class Clinical-Stage T-Cell Engagers

VIR

Argus Research

9 months ago

VIR: What does Argus have to say about VIR?

Vir Biotechnology to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference
VIR

Business Wire

9 months ago

Vir Biotechnology to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference

VIR

Argus Research

9 months ago

VIR: Raising target price to $9.00

Wall Street Analysts See a 258.38% Upside in Vir Biotechnology (VIR): Can the Stock Really Move This High?
VIR

Zacks

10 months ago

Wall Street Analysts See a 258.38% Upside in Vir Biotechnology (VIR): Can the Stock Really Move This High?

Vir Biotechnology, Inc. (VIR) Reports Q2 Loss, Lags Revenue Estimates
VIR

Zacks

10 months ago

Vir Biotechnology, Inc. (VIR) Reports Q2 Loss, Lags Revenue Estimates

Vir Biotechnology Reports Second Quarter 2024 Financial Results and Announces Strategic Restructuring to Prioritize Clinical-Stage Pipeline Opportunities
VIR

Business Wire

10 months ago

Vir Biotechnology Reports Second Quarter 2024 Financial Results and Announces Strategic Restructuring to Prioritize Clinical-Stage Pipeline Opportunities

Vir Biotechnology Acts on Expanded Strategy of Powering the Immune System Through Exclusive Worldwide License Agreement with Sanofi for Multiple Potential Best-in-Class Clinical-Stage T-cell Engagers
VIR

Business Wire

10 months ago

Vir Biotechnology Acts on Expanded Strategy of Powering the Immune System Through Exclusive Worldwide License Agreement with Sanofi for Multiple Potential Best-in-Class Clinical-Stage T-cell Engagers

VIR

Argus Research

10 months ago

VIR: What does Argus have to say about VIR?

Vir Biotechnology to Report Second Quarter 2024 Financial Results on August 1, 2024
VIR

Business Wire

10 months ago

Vir Biotechnology to Report Second Quarter 2024 Financial Results on August 1, 2024

VIR

Argus Research

a year ago

VIR: Raising target price to $11.00

VIR

Argus Research

a year ago

VIR: Rating increased to a HOLD

VIR

Argus Research

a year ago

VIR: What does Argus have to say about VIR?

Vir Biotechnology Receives FDA IND Clearance and Fast Track Designation for Tobevibart and Elebsiran for the Treatment of Chronic Hepatitis Delta Infection
VIR

Business Wire

a year ago

Vir Biotechnology Receives FDA IND Clearance and Fast Track Designation for Tobevibart and Elebsiran for the Treatment of Chronic Hepatitis Delta Infection

Is Vir Biotechnology (NASDAQ:VIR) In A Good Position To Deliver On Growth Plans?
VIR

Simply Wall St.

a year ago

Is Vir Biotechnology (NASDAQ:VIR) In A Good Position To Deliver On Growth Plans?

Vir Biotechnology (VIR) Up on Positive Data From HDV Study
VIR

Zacks

a year ago

Vir Biotechnology (VIR) Up on Positive Data From HDV Study

Why Is Infectious Disease-Focused Vir Biotechnology Stock Trading Higher On Wednesday?
VIR

Benzinga

a year ago

Why Is Infectious Disease-Focused Vir Biotechnology Stock Trading Higher On Wednesday?

Tobevibart Monotherapy and Combination Therapy with Elebsiran Achieved High Virologic Response and ALT Normalization in People Living with the Hepatitis Delta Virus After 12 and 24 Weeks of Treatment
VIR

Business Wire

a year ago

Tobevibart Monotherapy and Combination Therapy with Elebsiran Achieved High Virologic Response and ALT Normalization in People Living with the Hepatitis Delta Virus After 12 and 24 Weeks of Treatment

Vir Biotechnology to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference
VIR

Business Wire

a year ago

Vir Biotechnology to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference

Vir Biotechnology Appoints Mark Eisner, M.D., M.P.H. as Chief Medical Officer
VIR

Business Wire

a year ago

Vir Biotechnology Appoints Mark Eisner, M.D., M.P.H. as Chief Medical Officer

Vir Biotechnology to Host 2024 Annual Meeting of Stockholders
VIR

Business Wire

a year ago

Vir Biotechnology to Host 2024 Annual Meeting of Stockholders

Multiple Abstracts Highlighting Vir Biotechnology’s Latest Hepatitis Delta & B Data Accepted for Presentation at the EASL Congress 2024
VIR

Business Wire

a year ago

Multiple Abstracts Highlighting Vir Biotechnology’s Latest Hepatitis Delta & B Data Accepted for Presentation at the EASL Congress 2024

Vir Biotechnology Announces SOLSTICE Data to be Featured as an Oral Presentation at the European Association for the Study of the Liver (EASL) Congress 2024
VIR

Business Wire

a year ago

Vir Biotechnology Announces SOLSTICE Data to be Featured as an Oral Presentation at the European Association for the Study of the Liver (EASL) Congress 2024

Analysts Just Shipped A Stunning Upgrade To Their Vir Biotechnology, Inc. (NASDAQ:VIR) Estimates
VIR

Simply Wall St.

a year ago

Analysts Just Shipped A Stunning Upgrade To Their Vir Biotechnology, Inc. (NASDAQ:VIR) Estimates

Wall Street Analysts Think Vir Biotechnology (VIR) Could Surge 188.65%: Read This Before Placing a Bet
VIR

Zacks

a year ago

Wall Street Analysts Think Vir Biotechnology (VIR) Could Surge 188.65%: Read This Before Placing a Bet

Share on Social Networks: